Levodopa, dopamine agonist agents do not require conversion and storage because they by pass the failing nigrostriatal pathway to directly stimulate receptors in the normal striatum. They are the most effective class of drugs for PD after levodopa. In early disease, they provide an effective ...
Levodopa therapy is the gold standard for symptomatic treatment of Parkinson's disease (PD), but levodopa and/or dopamine (DA)-induced neurotoxicity have been reported in both in vitro and in vivo experimental studies. To clarify the beneficial effects of combining DA agonists with levodopa in PD...
Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA, receptors in the striatopallidal complex 1995. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: Correlation with changes in dopamine and GABAA receptors in the striatopallidal ...
Key exclusion criteria included the following: history of dyskinesia that was exclusively diphasic, OFF state, myoclonic, dystonic, or akathetic without peak-dose dyskinesia; neurosurgical intervention related to PD; atypical parkinsonism; levodopa- or dopamine agonist–induced psychosis; cognitive impairmen...
K Dyskinesias are the most common motor side effect associated with chronic LD treatment, but are not as prevalent following dopamine receptor agonist therapy. K The use of dopamine receptor agonists is often complicated by the development of major autonomic and psychiatric side effects that outweigh...
Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists Levodopa therapy is essential for patients in the advanced stages of Parkinson's disease. However, at early stages, DA agonist therapy has similar efficacy... T Kondo - 《Journal of Neurology》 被引量: 34发表: 200...
Objective To compare the long-term effects on patient-rated quality of life of adding a dopamine agonist vs a dopamine reuptake inhibitor (DRI), either a monoamine oxidase type B (MAO-B) inhibitor or a catechol-O-methyltransferase (COMT) inhibitor, to levodopa therapy for the treatment of pat...
Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release PURPOSE: Levodopa and dopamine (DA) agonist therapy are two common treatments for Parkinson's disease (PD). There is controversy about the effects of these... V Sossi,K Dinelle,M Schulzer,... -...
Apomorphine hydrochloride injection (Apokyn; Britannia Pharmaceuticals, Reading, UK) is a currently available fast-acting dopamine agonist that offers onset of clinical benefit within 10–20 minutes, but requires a subcutaneous injection to be administered and may be associated with nausea, hypotension, ...
a highly lipophilic dopamine-receptor agonist delivered via transdermal patches has been shown to improve subjective sleep quality in PD patients with RBD74and was found to be effective in both early75and advanced stage PD patients.76The dopamine agonist, ropinirole in its 24-h prolonged release fo...